Medtronic (MDT) said Thursday evening that the Centers for Medicare & Medicaid Services has issued a proposed national coverage determination for the company's Symplicity Spyral renal denervation system, triggering a 30-day public comment period.
The proposed decision marks a key step toward potential nationwide Medicare coverage for the minimally invasive system, which is designed to treat high blood pressure by delivering radiofrequency energy to overactive nerves near the kidneys, the healthcare technology company said.
The final coverage decision is expected on or before Oct. 8, and until then, coverage for Medicare patients will continue to be determined on a case-by-case basis, the company added.
Shares of Medtronic were slightly higher in recent Friday trading.
Price: 89.82, Change: +0.42, Percent Change: +0.47
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。